Related Experiment Video

Updated: Jun 21, 2026

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets

Lisa Getty-Kaushik1, Ann-Marie T Richard, Jude T Deeney

  • 1Obesity Research Center, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.

Obesity (Silver Spring, Md.)
|August 1, 2009
PubMed

Insights

Rimonabant, a CB1 receptor antagonist, reduces elevated basal insulin secretion in islets from obese or diet-induced obese rats. It also affects glucose-stimulated insulin secretion (GSIS) differently in lean versus obese or diet-induced obese rat islets.

Area of Science:

  • Endocrinology
  • Metabolic Syndrome Research
  • Islet Biology

Background:

  • Type 2 diabetes and obesity involve dysregulated insulin secretion and elevated free fatty acids.
  • CB1 receptor antagonist Rimonabant shows potential for improving glucose homeostasis.
  • Direct effects of Rimonabant on pancreatic islets remain unclear.

Purpose of the Study:

  • To investigate the direct impact of Rimonabant on insulin secretion from pancreatic islets in models of obesity and diet-induced metabolic dysfunction.
  • To determine if Rimonabant modulates basal and glucose-stimulated insulin secretion (GSIS) in lean, obese Zucker (ZF), and Zucker Diabetic Fatty (ZDF) rat islets.

Main Methods:

  • Incubation of rat islets (lean, ZF, ZDF) for 24 hours with glucose and palmitate (GL), with or without Rimonabant.
  • Measurement of insulin secretion at basal (3 mmol/l) and stimulatory (15 mmol/l) glucose concentrations.
  • Assessment of Rimonabant's effects on basal hypersecretion and the fold increase in GSIS.

Main Results:

  • Rimonabant significantly reduced elevated basal insulin secretion in islets from obese rats and GL-treated lean rats.
  • The fold increase in GSIS was not diminished by Rimonabant in obese or GL-treated lean rat islets.
  • Rimonabant decreased GSIS in lean rat islets but did not affect basal secretion, while its effect on GSIS in obese/GL-exposed islets was different.

Conclusions:

  • Rimonabant directly acts on pancreatic islets to reduce insulin secretion when it is pathologically elevated due to obesity or dietary factors.
  • Rimonabant's effects on insulin secretion differ between lean and metabolically compromised islets, suggesting context-dependent mechanisms.
  • These findings highlight Rimonabant's potential role in managing hyperinsulinemia associated with metabolic diseases.

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...